Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
Department of Oncology, Clinique Générale Beaulieu, Geneva, Switzerland.
Curr Oncol Rep. 2022 Dec;24(12):1851-1862. doi: 10.1007/s11912-022-01335-8. Epub 2022 Oct 18.
To describe the biological rationale of peripheral blood cells (PBC)-derived inflammatory indexes and assess the related prognostic scores for patients with advanced non-small cell lung cancer (aNSCLC) treated with immune-checkpoint inhibitors (ICI).
Inflammatory indexes based on PBC may indicate a pro-inflammatory condition affecting the immune response to cancer. The lung immune prognostic index (LIPI), consisting of derived neutrophils-to-lymphocyte ratio (NLR) and lactate dehydrogenase, is a validated prognostic tool, especially for pretreated aNSCLC patients, where the combination of NLR and PD-L1 tumour expression might also be predictive of immunotherapy benefit. In untreated high-PD-L1 aNSCLC patients, the Lung-Immune-Prognostic score (LIPS), including NLR, ECOG PS and concomitant steroids, is prognostic, and its modified version might indicate patients with favourable outcomes despite an ECOG PS of 2. NLR times platelets (i.e., SII), included in the NHS-Lung score, might improve the prognostication for combined chemoimmunotherapy. PBC-derived inflammatory indexes and related scores represent accurate, reproducible and non-expensive prognostic tools with clinical and research utility.
描述外周血细胞（PBC）衍生的炎症指标的生物学原理，并评估其用于评估接受免疫检查点抑制剂（ICI）治疗的晚期非小细胞肺癌（aNSCLC）患者的相关预后评分。
基于 PBC 的炎症指标可能提示影响癌症免疫反应的促炎状态。肺免疫预后指数（LIPI）由衍生的中性粒细胞与淋巴细胞比值（NLR）和乳酸脱氢酶组成，是一种经过验证的预后工具，特别是对于预处理的 aNSCLC 患者，NLR 与 PD-L1 肿瘤表达的联合也可能预测免疫治疗的获益。在未经治疗的高 PD-L1 aNSCLC 患者中，包括 NLR、ECOG PS 和同时使用类固醇的肺免疫预后评分（LIPS）是预后指标，其改良版本可能表明尽管 ECOG PS 为 2，但患者仍有良好的结局。包括在 NHS-Lung 评分中的 NLR 乘以血小板（即 SII）可能改善联合化疗免疫治疗的预后。PBC 衍生的炎症指标和相关评分是具有临床和研究实用性的准确、可重复且经济实惠的预后工具。
